Key facts
- This page summarizes Kirk Taylor's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 May 2023, 16:24.
Kirk Taylor - 01 May 2023 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- BCLI
- Reported as of
- 01 May 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Kirk Taylor
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Kirk Taylor filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 01 May 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCLI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 01 May 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCLI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +80,000
- Change %
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 01 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $2.99
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.
Footnote F2
The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.